Last reviewed · How we verify
Solifenacin for 24 weeks
Solifenacin blocks muscarinic M3 receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.
Solifenacin blocks muscarinic M3 receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urgency, frequency, and urge incontinence.
At a glance
| Generic name | Solifenacin for 24 weeks |
|---|---|
| Also known as | Vesicare |
| Sponsor | National Taiwan University Hospital |
| Drug class | Muscarinic M3 receptor antagonist |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Solifenacin is a selective antagonist of the M3 muscarinic acetylcholine receptor, which is abundant in bladder detrusor muscle. By blocking these receptors, it inhibits acetylcholine-mediated smooth muscle contractions, thereby increasing bladder capacity and reducing the frequency and urgency of micturition. This mechanism makes it effective for treating overactive bladder symptoms.
Approved indications
- Overactive bladder with symptoms of urgency, frequency, and urge incontinence
Common side effects
- Dry mouth
- Constipation
- Blurred vision
- Urinary retention
- Headache
Key clinical trials
- A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence (PHASE3)
- Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients (PHASE4)
- Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Solifenacin for 24 weeks CI brief — competitive landscape report
- Solifenacin for 24 weeks updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI